Investment

Medline raised its full-year organic sales guidance to 8.5–9.5% despite a 25.8% drop in net income driven by tariff costs

Madrigal's MASH therapy Rezdiffra has crossed blockbuster sales thresholds as the company expands its pipeline with a licensed siRNA targeting PNPLA3.

The Burlington-based vascular device maker reported Q1 2026 sales of $66.6m, with EPS up 42% year-on-year and full-year guidance raised.

The medical technology group beat its adjusted EPS guidance and named Stuart Essig as CEO as its Tissue Reconstruction unit led organic growth.

The Jena-based biopharmaceutical company sold 75 million ordinary shares at $2.00 each, attracting a broad syndicate of healthcare-focused institutional investors.

The coagulation-disorder biotech raised approximately $301.5m gross, listing under ticker COAG with two clinical-stage antibody programmes in its pipeline.

EyePoint said its DURAVYU Phase 3 wet AMD trials remain on track for topline data from mid-2026, backed by $223m in cash extending into

The Durham-based medical-technology company reported Q1 net sales of $132.1m and lifted its full-year adjusted EPS and cash-flow forecasts.

BEYONTTRA becomes the first near-complete TTR stabiliser approved in Brazil, backed by Phase 3 data showing a 42% cut in cardiovascular mortality and hospitalisation.

The Boston-based clinical-stage biotech priced 16.7 million shares at $18 each to fund inhaled antifibrotic programmes targeting pulmonary fibrosis.

The Lyon-based vaccine specialist raised €37m at closing, with up to €47m more if warrants tied to FDA Lyme approval are exercised.

The Berlin biotech selected TCX-201 as its first clinical candidate and targets a CTA filing in 2027 for gastrointestinal and solid tumours.

The Nantes-based biotech reported a sharp swing to loss in 2025 and warned auditors may issue a going concern qualification absent new financing.

The Menlo Park psoriasis biotech is seeking up to $575m including an overallotment option, with Leerink Partners and Goldman Sachs among the bookrunners.

The Bedford-based biotech has opened a three-year extension study for AXPAXLI, its long-acting intravitreal hydrogel, aiming to demonstrate disease-modifying benefit in

The French ophthalmology biotech doubled revenue to €16.8m in 2025 and expects to file its glaucoma candidate NCX 470 with the FDA by summer

Mesoblast has hit its 300-patient recruitment target for MSB-DR004, with topline data expected mid-2027 ahead of a planned FDA BLA filing.

Watertown biotech Kestrel has entered a warrant deal with AbbVie worth up to $1.45bn alongside dosing the first patient in its KST-6051 Phase

The Geneva-based allosteric modulator specialist ended 2025 with thinning cash reserves but two Phase 2 assets in hand after regaining rights to ADX71149.

your potential is a fire; don't let the world dampen your spark. Stay curious, act with kindness, and remember that even small steps lead to massive change.